This could in turn cause [1] self-engagement among macrophages, and [2] the competition between anti-SIRPA antibodies and other therapeutic antibodies (e.g., anti-GD2) for FcγR binding, which would dampen the therapeutic efficacy of the tumor-opsonizing antibodies. Here, SIRPA is linked to neoplasm.